AR and prostate cancer: Different cancers can overexpress IRE1α to mediate progression; for example, luminal breast cancer overexpression of IRE1α leads to the RIDD-mediated degradation of tumor suppressor miR-3607 and overexpression of oncogene GTPase RAB3B [131], and castration-resistant prostate cancer overexpression of IRE1α activates IL-6 and the androgen receptor positive feedback loop [131].